-+ 0.00%
-+ 0.00%
-+ 0.00%

Indications for treatment and prevention of human parainfluenza virus infection with YKYY018, a subsidiary of Yuekang Pharmaceutical (688658.SH), were approved for clinical trials by the FDA

Zhitongcaijing·11/12/2026 10:09:27
Listen to the news

Zhitong Finance App News, Yuekang Pharmaceutical (688658.SH) issued an announcement. The company's subsidiary Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. (“Yuekang Kechuang”) recently received a letter from the US Food and Drug Administration (“FDA”) to agree to the clinical trial application of YKYY018 atomized inhaler for the treatment and prevention of human parainfluenza virus infection.

Currently, clinical phase I clinical research of YKYY018 nebulized inhaler against RSV infection is progressing steadily. This clinical trial application for drug candidate treatment and prevention of HPIV infection has been approved by the FDA. It is another important development following approval of clinical trial applications related to RSV and hMPV. It has further expanded the clinical development layout of YKYY018 atomized inhalers in the field of respiratory viral infection prevention and treatment, laying the foundation for future clinical treatment needs of various respiratory viral infections.